NeoGenomics Corp (NEO) - יתרות מזומנים בחישוב למניה

NeoGenomics, Inc. (NEO) maintains its leadership in the complex oncology diagnostics segment through close ties with medical centers. This cash per share chart clearly demonstrates liquidity dynamics, where 1.08 captures the value of this parameter. The company generates revenue from genetic tests for physicians and support for pharmaceutical projects, while the balance between B2B clinics and biopharmaceuticals effectively stabilizes the overall business margins.
פילוחי מדדים מקיפים ואנליטיקה עבור NeoGenomics Inc (NEO)

NeoGenomics, Inc. (NEO) maintains a liquid reserve that ensures financial stability during the implementation of costly NGS tests and the scaling of personalized medicine. An analysis of the cash-per-share history allows for a real-time assessment of the daily available capital per security, where sharp amplitude fluctuations signal inventory volatility risks, directly impacting the fundamental fair value assessment of the company.